SGN-ALPV

N/A

Report date: 2024/02/05 14:06:33

Base Information

Drug NameSGN-ALPV
Drug Alias NameSGN-ALPV
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Cleavable peptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAlkaline phosphatase, placental type modulatorsTubulin polymerisation inhibitors
TargetsAlkaline phosphatase, placental typeTubulin
Therapy Area/IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeagen Inc
Active IndicationsN/A
Inactive IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 

Other Information

ATC CodeN/A
Related LinksN/A